Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO )
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19409 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Kamel Laribi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, Le Mans Hospital, Le Mans, France. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Waldenstrom Macroglobulinemia, Rituximab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
The bendamustine–rituximab (BR) schedule is an efficient first‐line therapy in Waldenström macroglobulinaemia (WM). A previous analysis of 69 patients who received this treatment confirmed a high response rate and good progression‐free (PFS) and overall survival (OS). With a median follow‐up of 76.1 months (95% confidence interval [CI] 69.9–80.6), 5‐year outcome is still excellent at 66.63% (95% CI 56.09–79.17) for PFS and 80.01% (95% CI 70.82–90.41) for OS. The rate of secondary cancers is 17.66% (IQR 7.99–27.64) at 66 months. Relapsed patients who received ibrutinib as second‐line clearly benefited from this schedule. This confirms current recommendations suggesting BR long‐term efficacy as first‐line option in WM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology Department, Le Mans Hospital, Le Mans, France.
- Cellular Haematology, Biology and Pathology Center, Lille Regional and University Hospital and INSERM UMR 1172, IRCL, Lille, France.
- Haematology Clinic, Cochin Hospital, APHP, Paris, France.
- Haematology and Oncology Clinic, André Mignot Hospital, Versailles Hospital, Versailles, France.
- Haematology Clinic, Montpellier University Hospital, Montpellier, France.
- Haematology Department, APHP, Sorbonne University, University Hospital La Pitié Salpêtrière-Charles Foix, Paris, France.
ORCID-Profile: Kamel Laribi, Charles Herbaux, Damien Roos-Weil, Ronan Le Calloch
Zitieren
APA
Laribi, K., Poulain, S., Willems, L., Merabet, F., Herbaux, C., Roos-Weil, D., Laribi de Materre, I., Roussel, X., Nudel, M., Tricot, S., Dupuis, J., Le Calloch, R., Bareau, B., & Leblond, V. (2024). Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO ). British Journal of Haematology. https://doi.org/10.1111/bjh.19409
Vancouver
Laribi K, Poulain S, Willems L, Merabet F, Herbaux C, Roos-Weil D, et al. Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO ). British Journal of Haematology. 2024. doi:10.1111/bjh.19409
BibTeX
@article{Laribi2024,
author = {Laribi, Kamel and Poulain, Stéphanie and Willems, Lise and Merabet, Fatiha and Herbaux, Charles and Roos-Weil, Damien and Laribi de Materre, Inès and Roussel, Xavier and Nudel, Morgane and Tricot, Sabine and Dupuis, Jehan and Le Calloch, Ronan and Bareau, Benoit and Leblond, Véronique},
title = {Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization ( FILO )},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19409}
}
EUVIMED